Better Treatments for
Microvessel Diseases

About Ingenia

INGENIA Therapeutics Inc. (“Ingenia”) is a privately held biotechnology company specializing in the discovery and development of therapeutic antibody candidates for patient populations suffering from defective micro-vessel and progressive chronic diseases. Currently, Ingenia focuses on the treatment of damaged capillary-associated indications with high unmet clinical needs and has exclusive global rights to develop therapeutic antibody candidates for restoring damaged capillaries to their healthy state by modulating endothelial cell signaling pathways to recover damaged capillary functions.

Pipeline

INGENIA has two lead product candidates in its pipeline:

• IGT-427 is a bi-specific antibody with a site-specific bioconjugate for an extended ocular half-life. It is an early-stage asset, targeting primarily the DME market.
• IGT-302 is a humanized monoclonal antibody with a site-specific bioconjugate for an extended ocular half-life. It is targeting primarily glaucoma.